logo

For the Inventor, By the Inventor

Lexington, MA, United States of America

Translate Bio, Inc.


USPTO Granted Patents = 155



Trademarks = 1

Forward Citations = 574

Loading Chart...
Loading Chart...

61 inventors (with patents filed for the assignee):

goldMedal Frank DeRosa (130 out of 144 patents)

silverMedal Michael W Heartlein (130 out of 176 patents)

bronzeMedal Shrirang Karve (53 out of 55 patents)

4.  Braydon Charles Guild (43 out of 58 patents)

5.  Anusha Dias (33 out of 34 patents)

6.  Arthur Mertz Krieg (13 out of 68 patents)

7.  Romesh R Subramanian (12 out of 70 patents)

8.  Jonathan Abysalh (10 out of 10 patents)

9.  Lianne Smith (10 out of 12 patents)

10.  Zarna Patel (9 out of 10 patents)

11.  Daniel Crawford (8 out of 9 patents)

12.  Yi Zhang (7 out of 7 patents)

13.  Frank Derosa (7 out of 7 patents)

14.  Jeannie T Lee (6 out of 28 patents)

15.  Ashish Sarode (6 out of 7 patents)


Core Competencies:
Ionizable Cationic Lipids
Cationic Polymers
Messenger RNA Vaccines
Lipid Nanoparticle Formulations
Nucleic Acid Delivery
Thioester Cationic Lipids
Synthetic Nucleic Acids
CNS Delivery of mRNA
Purification of Messenger RNA
Vitamin Cationic Lipids
mRNA Therapy
Ribonucleic Acids

155 patents:

1. 12514932 - PEG lipidoid compounds (2026-01-06),
2. 12509666 - MRNA THERAPY FOR PHENYLKETONURIA (2025-12-30),
3. 12459885 - Ionizable cationic lipids (2025-11-04),
4. 12453759 - Di-thioester cationic lipids (2025-10-28),
5. 12453739 - Synergistic enhancement of the delivery of nucleic acids via blended formulations (2025-10-28),
6. 12421538 - Quantitative assessment for cap efficiency of messenger RNA (2025-09-23),
7. 12410422 - Methods for purification of messenger RNA (2025-09-09),
8. 12377053 - Cationic polymers (2025-08-05),
9. 12370262 - Messenger RNA vaccines and uses thereof (2025-07-29),
10. 12370238 - Composition and methods for treatment of primary ciliary dyskinesia (2025-07-29),
11. 12331005 - Ionizable cationic lipids (2025-06-17),
12. 12318489 - Nanoparticle formulations for delivery of nucleic acid complexes (2025-06-03),
13. 12280147 - PEG lipidoid compounds (2025-04-21),
14. 12280117 - Lipid nanoparticle formulations for delivery of MRNA (2025-04-21),
15. 12268754 - Composition and methods for treatment of ornithine transcarbamylase deficiency (2025-04-08),
Translate Bio, Inc. is a clinical-stage mRNA therapeutics company. The company focuses on developing transformative medicines to treat diseases caused by protein or gene dysfunction. With its proprietary mRNA platform, Translate Bio aims to address a broad range of diseases including rare genetic disorders, pulmonary diseases, and oncology. The company's innovative approach utilizes messenger RNA (mRNA) to instruct cells in the body to produce therapeutic proteins with the goal of restoring health and function.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

155 Patents

#4 in Lexington, MA

#134 in Massachusetts

#2,476 in US

#5,171 in the World

...
Lexington, MA, United States of America

Translate Bio, Inc.

Forward Citations = 574

61 inventors:

goldMedal Frank DeRosa (130 out of 144 patents)

silverMedal Michael W Heartlein (130 out of 176 patents)

bronzeMedal Shrirang Karve (53 out of 55 patents)

4.  Braydon Charles Guild (43 out of 58 patents)

5.  Anusha Dias (33 out of 34 patents)

Please report any incorrect information to support@idiyas.com
Loading…